Cantor Fitzgerald Maintains Their Buy Rating on Nightstar Therapeutics Limited (NITE)


In a report released today, Elemer Piros from Cantor Fitzgerald maintained a Buy rating on Nightstar Therapeutics Limited (NITE), with a price target of $36. The company’s shares opened today at $12.01, close to its 52-week low of $9.59.

Piros observed:

“Nightstar is developing AAV-vector-based gene therapies for ophthalmological indications. Nightstar is currently conducting a Phase 3 (STAR) study of the treatment of choroideremia. Nightstar has shown positive Phase 2 data in multiple investigator sponsor led trials in four different countries. In our view, Nightstar has a potential first mover advantage in this indication, where a large unmet medical need exists.”

According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.5% and a 33.1% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nightstar Therapeutics Limited with a $35.14 average price target, a 192.6% upside from current levels. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $40 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $29.55 and a one-year low of $9.59. Currently, Nightstar Therapeutics Limited has an average volume of 154K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts